Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
Although there have been many improvements in prognosis for patients with cancer, anticancer therapies are burdened by the risk of cardiovascular toxicity. Heart failure is one of the most dramatic clinical expressions of cardiotoxicity, and it may occur acutely or appear years after treatment. This...
Saved in:
Main Authors: | Alessandra Cuomo, Alessio Rodolico, Amalia Galdieri, Michele Russo, Giacomo Campi, Riccardo Franco, Dalila Bruno, Luisa Aran, Antonio Carannante, Umberto Attanasio, Carlo G Tocchetti, Gilda Varricchi, Valentina Mercurio |
---|---|
Format: | article |
Language: | EN |
Published: |
Radcliffe Medical Media
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/350633c3d3f44e04b7903c622d9e8c1e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Reversible cardiotoxicity in a 54-year-old woman treated with trastuzumab
by: Martins,Sandro José, et al.
Published: (2012) -
Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy
by: Giulia Bacchiani, et al.
Published: (2017) -
Aldose reductase inhibitor increases doxorubicin-sensitivity of colon cancer cells and decreases cardiotoxicity
by: Himangshu Sonowal, et al.
Published: (2017) -
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
by: Muhammad Mustafa Alhussein, MD, et al.
Published: (2021) -
Non-invasive cardiac imaging for evaluation of cardiotoxicity in cancer patients - early detection and follow-up
by: Gabriel Vorobiof, et al.
Published: (2017)